BFO
VRTX icon

Boston Family Office’s Vertex Pharmaceuticals VRTX Stock Holding History

Boston Family Office’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$498K Buy
1,116
+370
+50% +$173K 0.03% 222
2025
Q4 		$338K Hold
746
– – 0.02% 247
2025
Q3 		$292K Sell
746
-50
-6% -$20.9K 0.02% 251
2025
Q2 		$354K Buy
796
+345
+76% +$159K 0.02% 227
2025
Q1 		$219K Sell
451
-100
-18% -$46.6K 0.02% 267
2024
Q4 		$222K Sell
551
-15
-3% -$6.95K 0.02% 261
2024
Q3 		$263K Buy
+566
New +$272K 0.02% 244

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Boston Family Office's VRTX Position: Q1 2026 in Review

Boston Family Office increased its Vertex Pharmaceuticals (VRTX) stake by 50% in Q1 2026, buying an estimated $173K and bringing the position to 1,116 shares worth $498K. The position accounts for 0.03% of the portfolio, ranked #222.

Boston Family Office first reported a position in VRTX in Q3 2024 and has held it in 7 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Boston Family Office held 1,116 shares of Vertex Pharmaceuticals worth $498K as of Q1 2026.
  • Boston Family Office bought 370 Vertex Pharmaceuticals shares in Q1 2026, an estimated $173K.
  • Vertex Pharmaceuticals made up 0.03% of Boston Family Office's portfolio in Q1 2026, its #222 holding.
  • Boston Family Office first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Boston Family Office's 13F filing for Q1 2026, filed 13 May 2026.